At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…
Read More
A combination of chemotherapy and endocrine therapy offers the promise of long-term recurrence-free survival for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer, despite having a biologically high risk of disease recurrence. Yesterday’s Late-Breaking…
Read More
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer. Result from the BEACON study have shown for the first time that a combination of three…
Read More
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge. Advances in cancer research and the regulatory approval of new agents do not usually…
Read More
Rechallenge with PD-1/PD-L1 inhibitors after a (un)planned interruption may offer a potential safety net for patients with disease progression. At ESMO Congress 2019, results from a study systematically investigating this approach for the first time…
Read More
The phase III trial confirms that targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy, but debate is open on whether results are clinically meaningful. In view of encouraging results in the treatment…
Read More
Ripretinib as fourth-line therapy showed to improve progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) in the phase III INVICTUS trial presented today. According to Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland,…
Watch Here